At present, the clinical needs of central nervous system diseases such as chronic hepatitis B, epilepsy, neuropathic pain, depression, and stroke have not been met.
It is reported, “Weimeng Pharmaceutical has completed the joint investment of Zeyue Capital and Shenzhen Venture Capital, and Zhilang Venture Capital has invested nearly 100 million Pre-A round of financing. Prior to this, the company was awarded the Angel Wheel investment by Lenovo Star, Mint Angel Fund and Zhilang Venture.
This round of financing will be used for the core project of the “Shenzhen Medicine” – Hepatitis B Virus (HBV) nucleocapsid inhibitor clinical phase 1 study, as well as treatment of epilepsy, Clinical application research and development of follow-up pipeline projects for neuropathic pain and stroke programs.
Founded in October 2015, 挚 医药 医药 is focused on Chronic Hepatitis B (CHB), Liver Diseases and Central Nervous Diseases Innovative drug research and development company. His founder, Dr. Chen Huanming, is a research and development executive at several pharmaceutical companies and contract research companies (CROs), promoting multiple drugs (antiviral, antitumor, central nervous system, anti-infective, etc.) into clinical research, transfer or listing. /span>, and published 36 papers in internationally important academic journals and holds 35 invention patents.
It is understood that there are currently 250 million hepatitis B virus carriers worldwide. In China, the number of carriers of hepatitis B virus is about 90 million, of which about 30 million are chronic hepatitis B patients (CHB). Chronic hepatitis B is one of the most common chronic infectious diseases in China. It has a high incidence, is contagious, has a poor prognosis, and is difficult to cure. Long-term complications include cirrhosis, liver failure and liver. Cellular cancer, etc. Since CNB is a disease mainly caused by inflammatory lesions of the liver caused by HBV, the therapeutic goal of CHB is to maximize the long-term inhibition of hepatitis B virus replication and reduce hepatic inflammatory necrosis and fibrosis. However, as of now, no treatment has been available to achieve complete clearance of HBV. The patient’s condition will increase as soon as the drug or virus is stopped.
In response to the complexity of the cause of liver disease, the strategy of “Zhenmeng Medicine” is to develop a variety of new and effective anti-B types.Hepatitis virus (HBV) drugs, combined with multi-directional inhibition of HBV; at the same time, through the use of new immunomodulators, restore the patient’s immune function, and ultimately achieve a functional cure for chronic hepatitis B. In addition, the HBV nucleocapsid inhibitor of the core project of 挚 医药 医药 has completed the IND application study and is expected to enter clinical research in early 2020.
The “Xineng Medicine” R&D pipeline covers multiple links of the whole life cycle of hepatitis B virus and neurological diseases
In addition to the treatment of hepatitis B, “挚盟医药” has also openstarting the treatment of nervous system diseases such as stroke, epilepsy, neuropathic pain (such as cancer pain), depression, etc. Fields, research and development of small molecule innovative drugs.
“China Stroke Prevention Report 2018” pointed out that with the aging of society, the unhealthy lifestyle of residents is prevalent, and the risk factors of stroke are generally exposed. ChinaThe incidence of stroke is sharp Climb and present a trend of rapid growth and youthfulness in low-income groups. 2016 global disease burden (GBD) data show that stroke is the cause of China’s lifeThe first cause of life-year loss (YLL). The report also said that the incidence of cerebrovascular disease in China is expected to increase by about 50% in 2010 compared with 2010.
The incidence of ischemic stroke in China is 276.75/100,000 in 2016
The market for strokes is huge and there is a lot of growth.Between, multiple nerves can be found in the latest 2019 medical insurance catalogue. Internal medicine assisted medication was transferred to make room for drugs with real clinical effects in the future. At present, it is known that the drug development in the stroke market is “Plo Pharmaceutical“, “Shanghai Medicine“, “Tian Shi Li” and so on. Among them, Sofadil developed by “Pullo Pharmaceutical” is also a small molecule compound, which has a dual brain neuroprotective mechanism, and is currently undergoing phase II clinical data statistics. The project was jointly developed by “Pullo Pharmaceuticals” and GNT Pharm of South Korea, and was supported by the national “Major New Drug Creation” technology special project, and “Pullo Pharmaceutical” obtained its Chinese rights.
And “Shanghai Pharmaceutical” is cooperating with “Shuntian Medicine” and will contribute RMB 260 million.
The exclusive interest in the development, production and sales of the LT3001 project in mainland China. LT3001 is the world’s first new treatment for acute stroke combined with targeted thrombolysis and neuroprotection. Compared with the marketed thrombolytic drugs, LT3001 has the potential to prolong the treatment time window without increasing the risk of bleeding. It can also scavenge free radicals, protect brain nerve cells, and reduce reperfusion injury and cerebral edema. Potential advantage.
Edit: Dreamer dishes
Image source: Pixabay